reports
TRACON Pharmaceuticals Announces it Will Wind Down Operations
TRACON Pharmaceuticals Announces it Will Wind Down Operations SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over...
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Wil...
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product...
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Cl...
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) --...
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results an...
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Ti...
TRACON to Report First Quarter 2024 Financial Results and Provide Corp...
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, managem...
TRACON Pharmaceuticals Announces Reverse Stock Split
TRACON Pharmaceuticals Announces Reverse Stock Split SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the Board) to amend the Company’s Amended and ...
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Piv...
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financ...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM East...
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results an...
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, Marc...
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pi...
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, toda...
TRACON Pharmaceuticals Announces License of Product Development Platfo...
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment. “We...
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results an...
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacif...
TRACON to Report Third Quarter 2023 Financial Results and Provide Corp...
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, November 9, 2023. In additio...
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceed...
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ENVASARC Phase 2 pivotal trial more...
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Co...
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview: H.C. Wainw...
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results a...
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific ...
TRACON to Report Second Quarter 2023 Financial Results and Provide Cor...
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition,...
TRACON Pharmaceuticals Announces Collection of Arbitration Award from ...
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of the ENVASARC Pivotal Trial SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has collected the previously announced arbitration award fr...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Dou...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded Independent Central Review Achieved to Date in Single Agent Envafolimab Cohort without any > Grade 2 Drug Related Toxicity Full ENVASARC Accrual Expected in Q4 SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceut...
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtua...
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will prese...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.